Testosterone Propionate

Status

No approved product. FDA-approved labeling existed for testosterone replacement in males with primary hypogonadism or hypogonadotropic hypogonadism; Drugs@FDA lists every human testosterone propionate product as discontinued (retrieved 25 October 2026). Schedule III controlled substance.

What it is

A short-acting testosterone ester requiring frequent injections.

What published research measured

A short-acting testosterone ester. The pharmacology of the ester is well understood — the shorter propionate chain means faster release and clearance than the longer esters, so serum concentrations peak and fall more sharply, requiring more frequent administration to avoid trough symptoms. Testosterone itself is the same molecule regardless of ester, so the substantial efficacy and safety literature summarized for cypionate applies to the hormone; what differs is the concentration-time profile. Injection site reactions are reported more commonly with this ester than with the longer-chain alternatives. It is less used clinically than the long-acting esters for this reason.

Source

FDA labeling for testosterone propionate injection

Sources

• Testosterone cypionate label (DailyMed)